Last reviewed · How we verify
X-396 Capsule
At a glance
| Generic name | X-396 Capsule |
|---|---|
| Also known as | Ensartinib, ensartinib |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases (PHASE2)
- A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions (PHASE1)
- Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer (PHASE2)
- X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (PHASE2)
- X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases (PHASE2)
- X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement (PHASE2)
- Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- X-396 Capsule CI brief — competitive landscape report
- X-396 Capsule updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI